Share Price and Basic Stock Data
Last Updated: November 8, 2025, 3:07 am
| PEG Ratio | -1.44 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Lyka Labs Ltd operates in the pharmaceuticals sector, focusing on the production of a diverse range of healthcare products. The company reported a share price of ₹93.6 and a market capitalization of ₹334 Cr. Over the past fiscal year, Lyka Labs demonstrated fluctuations in sales, with the latest quarterly sales for June 2024 reaching ₹30.11 Cr, an increase from ₹22.24 Cr in March 2023. Notably, the sales trajectory exhibited a significant rise from ₹17.82 Cr in December 2022 to ₹32.56 Cr in December 2023, indicating a positive trend in revenue generation. The trailing twelve months (TTM) sales stood at ₹141 Cr, reflecting an upward movement from ₹138 Cr projected for March 2025. Overall, revenue growth has been inconsistent, but the recent uptick suggests a potential recovery phase for the company, amidst a challenging market environment typical of the pharmaceutical industry.
Profitability and Efficiency Metrics
The profitability metrics for Lyka Labs reveal a mixed performance in recent quarters. The operating profit margin (OPM) stood at 11.14%, indicating a moderate level of profitability, albeit lower than the industry average. The net profit for the company recorded a modest ₹8 Cr, translating to a net profit margin of 5.72% for March 2025. However, the company faced challenges, as evidenced by negative net profits in several quarters, including a notable loss of ₹10.42 Cr in December 2022. The interest coverage ratio (ICR) was reported at 8.87x, suggesting a strong ability to cover interest expenses, which is favorable compared to industry norms. However, the return on equity (ROE) of 9.31% and return on capital employed (ROCE) of 9.91% indicate that the company must improve its efficiency to maximize shareholder value and compete effectively in the pharmaceuticals sector.
Balance Sheet Strength and Financial Ratios
Lyka Labs’ balance sheet exhibits a mix of strengths and challenges. The company reported total borrowings of ₹39 Cr, a significant reduction from ₹130 Cr in March 2022, showcasing improved financial discipline. Reserves increased to ₹68 Cr, providing a buffer for future investments and operational stability. The current ratio was reported at 1.45, indicating adequate liquidity to meet short-term obligations, which is favorable compared to typical sector standards. However, the price-to-book value (P/BV) ratio stood at 3.48x, suggesting the stock may be overvalued relative to its book value, which was ₹29.01 per share as of March 2025. The debt-to-equity ratio at 0.35 reflects a conservative leverage position, but the company must focus on enhancing its asset turnover ratio, which was recorded at 0.83%, to improve operational efficiency.
Shareholding Pattern and Investor Confidence
Investor confidence in Lyka Labs is illustrated by its shareholding pattern, where promoters hold 58.16% of the company, a stable increase from 47.58% in September 2022. This significant promoter stake suggests strong insider confidence in the company’s future prospects. Foreign institutional investors (FIIs) account for a mere 0.16%, while domestic institutional investors (DIIs) hold 0.66%, indicating limited institutional interest. The public shareholding stands at 41.02%, with a total of 28,189 shareholders, reflecting a diverse ownership base. The gradual increase in promoter holdings over recent quarters may signal a positive outlook for the company’s strategic direction. However, the low FII participation could raise concerns regarding the company’s attractiveness to foreign investors, which is crucial for future capital infusion and market credibility.
Outlook, Risks, and Final Insight
Looking ahead, Lyka Labs faces both opportunities and risks that could impact its performance. The recent upward trend in sales and profitability metrics suggests potential for recovery; however, the company must address operational inefficiencies and enhance its product offerings to remain competitive. Risks include the volatility of raw material prices, regulatory challenges inherent in the pharmaceutical sector, and the need for continuous innovation in product development. Additionally, the low institutional investor participation may hinder access to capital for future growth initiatives. Overall, while the company has demonstrated resilience with improving financial metrics, a focused strategy on operational improvement and market expansion will be critical for sustaining growth and enhancing shareholder value in the long term.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Lyka Labs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 137 Cr. | 109 | 247/84.3 | 31.1 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,906 Cr. | 450 | 479/192 | 110 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 46.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 36.9 Cr. | 25.2 | 29.1/17.0 | 38.5 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,608.79 Cr | 1,177.38 | 55.81 | 198.49 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 27.49 | 25.53 | 17.82 | 22.24 | 22.88 | 27.99 | 32.56 | 27.77 | 30.11 | 41.16 | 33.80 | 33.43 | 33.03 |
| Expenses | 21.18 | 20.50 | 15.61 | 18.94 | 20.24 | 23.82 | 25.69 | 25.75 | 26.40 | 36.21 | 28.61 | 29.35 | 29.35 |
| Operating Profit | 6.31 | 5.03 | 2.21 | 3.30 | 2.64 | 4.17 | 6.87 | 2.02 | 3.71 | 4.95 | 5.19 | 4.08 | 3.68 |
| OPM % | 22.95% | 19.70% | 12.40% | 14.84% | 11.54% | 14.90% | 21.10% | 7.27% | 12.32% | 12.03% | 15.36% | 12.20% | 11.14% |
| Other Income | 0.95 | 0.98 | -5.95 | 0.02 | 0.38 | -0.18 | 0.54 | 0.32 | 0.56 | 0.03 | 0.83 | 0.82 | 0.63 |
| Interest | 2.91 | 3.03 | 3.08 | 2.85 | 1.35 | 1.19 | 1.28 | 1.07 | 0.65 | 0.54 | 0.61 | 0.47 | 0.85 |
| Depreciation | 3.59 | 3.62 | 3.47 | 3.47 | 3.47 | 3.59 | 2.84 | 2.90 | 1.76 | 1.76 | 1.83 | 1.42 | 2.11 |
| Profit before tax | 0.76 | -0.64 | -10.29 | -3.00 | -1.80 | -0.79 | 3.29 | -1.63 | 1.86 | 2.68 | 3.58 | 3.01 | 1.35 |
| Tax % | 6.58% | -46.88% | 2.24% | 0.00% | 7.22% | -22.78% | 38.60% | 28.22% | 30.65% | 28.36% | 24.30% | 32.89% | 26.67% |
| Net Profit | 0.60 | -0.38 | -10.42 | -3.01 | -1.85 | -0.49 | 1.78 | -2.09 | 1.29 | 2.10 | 2.70 | 2.03 | 0.99 |
| EPS in Rs | 0.21 | -0.13 | -3.63 | -0.98 | -0.56 | -0.15 | 0.54 | -0.63 | 0.40 | 0.59 | 0.76 | 0.50 | 0.26 |
Last Updated: August 1, 2025, 5:50 pm
Below is a detailed analysis of the quarterly data for Lyka Labs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 33.03 Cr.. The value appears to be declining and may need further review. It has decreased from 33.43 Cr. (Mar 2025) to 33.03 Cr., marking a decrease of 0.40 Cr..
- For Expenses, as of Jun 2025, the value is 29.35 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 29.35 Cr..
- For Operating Profit, as of Jun 2025, the value is 3.68 Cr.. The value appears to be declining and may need further review. It has decreased from 4.08 Cr. (Mar 2025) to 3.68 Cr., marking a decrease of 0.40 Cr..
- For OPM %, as of Jun 2025, the value is 11.14%. The value appears to be declining and may need further review. It has decreased from 12.20% (Mar 2025) to 11.14%, marking a decrease of 1.06%.
- For Other Income, as of Jun 2025, the value is 0.63 Cr.. The value appears to be declining and may need further review. It has decreased from 0.82 Cr. (Mar 2025) to 0.63 Cr., marking a decrease of 0.19 Cr..
- For Interest, as of Jun 2025, the value is 0.85 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.47 Cr. (Mar 2025) to 0.85 Cr., marking an increase of 0.38 Cr..
- For Depreciation, as of Jun 2025, the value is 2.11 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.42 Cr. (Mar 2025) to 2.11 Cr., marking an increase of 0.69 Cr..
- For Profit before tax, as of Jun 2025, the value is 1.35 Cr.. The value appears to be declining and may need further review. It has decreased from 3.01 Cr. (Mar 2025) to 1.35 Cr., marking a decrease of 1.66 Cr..
- For Tax %, as of Jun 2025, the value is 26.67%. The value appears to be improving (decreasing) as expected. It has decreased from 32.89% (Mar 2025) to 26.67%, marking a decrease of 6.22%.
- For Net Profit, as of Jun 2025, the value is 0.99 Cr.. The value appears to be declining and may need further review. It has decreased from 2.03 Cr. (Mar 2025) to 0.99 Cr., marking a decrease of 1.04 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.26. The value appears to be declining and may need further review. It has decreased from 0.50 (Mar 2025) to 0.26, marking a decrease of 0.24.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:56 am
| Metric | Jun 2014n n 15m | Jun 2015 | Mar 2016n n 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 119 | 166 | 130 | 110 | 60 | 71 | 61 | 86 | 194 | 93 | 111 | 138 | 141 |
| Expenses | 111 | 139 | 110 | 87 | 63 | 73 | 65 | 67 | 93 | 76 | 95 | 121 | 124 |
| Operating Profit | 8 | 28 | 20 | 23 | -4 | -2 | -4 | 20 | 101 | 17 | 16 | 18 | 18 |
| OPM % | 7% | 17% | 16% | 21% | -6% | -3% | -6% | 23% | 52% | 18% | 14% | 13% | 13% |
| Other Income | 25 | 4 | 8 | -2 | 4 | 1 | -30 | 0 | -4 | -4 | 1 | 2 | 2 |
| Interest | 27 | 24 | 15 | 19 | 10 | 7 | 20 | 26 | 20 | 12 | 5 | 2 | 2 |
| Depreciation | 9 | 11 | 9 | 10 | 11 | 7 | 8 | 8 | 17 | 14 | 13 | 7 | 7 |
| Profit before tax | -3 | -3 | 4 | -8 | -20 | -15 | -62 | -14 | 59 | -13 | -1 | 11 | 11 |
| Tax % | 45% | 31% | -5% | -19% | -5% | -59% | 1% | -29% | 35% | -0% | 182% | 29% | |
| Net Profit | -5 | -5 | 4 | -7 | -19 | -6 | -63 | -10 | 38 | -13 | -3 | 8 | 8 |
| EPS in Rs | -3.05 | -2.29 | 1.67 | -2.51 | -6.14 | -1.97 | -21.10 | -4.03 | 13.59 | -4.30 | -0.75 | 2.24 | 2.11 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -171.43% | 68.42% | -950.00% | 84.13% | 480.00% | -134.21% | 76.92% | 366.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 239.85% | -1018.42% | 1034.13% | 395.87% | -614.21% | 211.13% | 289.74% |
Lyka Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 18% |
| 3 Years: | -11% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 18% |
| 3 Years: | -43% |
| TTM: | 681% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 39% |
| 3 Years: | -13% |
| 1 Year: | -40% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 0% |
| Last Year: | 9% |
Last Updated: September 5, 2025, 9:55 am
Balance Sheet
Last Updated: July 25, 2025, 2:50 pm
| Month | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 28 | 28 | 29 | 29 | 29 | 31 | 33 | 36 |
| Reserves | 30 | 20 | 22 | 16 | 21 | 15 | -43 | -54 | -15 | 15 | 35 | 68 |
| Borrowings | 164 | 137 | 121 | 126 | 113 | 96 | 141 | 163 | 130 | 75 | 59 | 39 |
| Other Liabilities | 113 | 100 | 77 | 88 | 67 | 76 | 73 | 52 | 42 | 31 | 30 | 33 |
| Total Liabilities | 329 | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 176 |
| Fixed Assets | 162 | 122 | 104 | 133 | 116 | 108 | 105 | 98 | 94 | 68 | 58 | 85 |
| CWIP | 22 | 27 | 30 | 24 | 28 | 31 | 28 | 26 | 18 | 16 | 23 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 145 | 130 | 107 | 94 | 85 | 77 | 68 | 66 | 74 | 67 | 76 | 90 |
| Total Assets | 329 | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 176 |
Below is a detailed analysis of the balance sheet data for Lyka Labs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 36.00 Cr.. The value appears strong and on an upward trend. It has increased from 33.00 Cr. (Mar 2024) to 36.00 Cr., marking an increase of 3.00 Cr..
- For Reserves, as of Mar 2025, the value is 68.00 Cr.. The value appears strong and on an upward trend. It has increased from 35.00 Cr. (Mar 2024) to 68.00 Cr., marking an increase of 33.00 Cr..
- For Borrowings, as of Mar 2025, the value is 39.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 59.00 Cr. (Mar 2024) to 39.00 Cr., marking a decrease of 20.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 33.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 30.00 Cr. (Mar 2024) to 33.00 Cr., marking an increase of 3.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 176.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 157.00 Cr. (Mar 2024) to 176.00 Cr., marking an increase of 19.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 85.00 Cr.. The value appears strong and on an upward trend. It has increased from 58.00 Cr. (Mar 2024) to 85.00 Cr., marking an increase of 27.00 Cr..
- For CWIP, as of Mar 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 23.00 Cr. (Mar 2024) to 1.00 Cr., marking a decrease of 22.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 90.00 Cr.. The value appears strong and on an upward trend. It has increased from 76.00 Cr. (Mar 2024) to 90.00 Cr., marking an increase of 14.00 Cr..
- For Total Assets, as of Mar 2025, the value is 176.00 Cr.. The value appears strong and on an upward trend. It has increased from 157.00 Cr. (Mar 2024) to 176.00 Cr., marking an increase of 19.00 Cr..
Notably, the Reserves (68.00 Cr.) exceed the Borrowings (39.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Jun 2014n n 15m | Jun 2015 | Mar 2016n n 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 8.00 | -109.00 | 20.00 | -103.00 | -117.00 | -98.00 | -145.00 | -143.00 | -29.00 | -58.00 | -43.00 | -21.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 209 | 124 | 121 | 97 | 125 | 75 | 48 | 37 | 35 | 79 | 89 | 114 |
| Inventory Days | 91 | 77 | 56 | 90 | 139 | 65 | 69 | 41 | 56 | 68 | 78 | 82 |
| Days Payable | 363 | 220 | 218 | 266 | 301 | 216 | 192 | 141 | 96 | 91 | 98 | 98 |
| Cash Conversion Cycle | -64 | -18 | -41 | -79 | -37 | -75 | -76 | -63 | -5 | 55 | 68 | 97 |
| Working Capital Days | -309 | -220 | -242 | -357 | -735 | -265 | -242 | -118 | -121 | -0 | 23 | 51 |
| ROCE % | 2% | 10% | 7% | 9% | -8% | -5% | -6% | 10% | 61% | 5% | 4% | 10% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.22 | -0.79 | -4.63 | 13.57 | -4.07 |
| Diluted EPS (Rs.) | 2.22 | -0.79 | -4.63 | 13.57 | -4.07 |
| Cash EPS (Rs.) | 4.12 | 3.08 | 0.32 | 19.45 | -0.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 29.01 | 20.60 | 14.81 | 4.70 | -8.75 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 29.01 | 20.60 | 14.81 | 4.70 | -8.75 |
| Revenue From Operations / Share (Rs.) | 38.81 | 33.60 | 30.33 | 67.65 | 30.06 |
| PBDIT / Share (Rs.) | 5.65 | 5.19 | 6.59 | 35.99 | 7.41 |
| PBIT / Share (Rs.) | 3.75 | 1.32 | 1.99 | 29.94 | 4.50 |
| PBT / Share (Rs.) | 3.12 | -0.28 | -4.29 | 20.65 | -4.93 |
| Net Profit / Share (Rs.) | 2.22 | -0.79 | -4.29 | 13.40 | -3.52 |
| NP After MI And SOA / Share (Rs.) | 2.24 | -0.75 | -4.30 | 13.59 | -4.03 |
| PBDIT Margin (%) | 14.56 | 15.44 | 21.74 | 53.19 | 24.63 |
| PBIT Margin (%) | 9.67 | 3.92 | 6.54 | 44.25 | 14.98 |
| PBT Margin (%) | 8.03 | -0.83 | -14.15 | 30.52 | -16.39 |
| Net Profit Margin (%) | 5.72 | -2.35 | -14.13 | 19.80 | -11.69 |
| NP After MI And SOA Margin (%) | 5.78 | -2.23 | -14.19 | 20.09 | -13.39 |
| Return on Networth / Equity (%) | 7.73 | -3.65 | -29.07 | 292.38 | 0.00 |
| Return on Capital Employeed (%) | 10.33 | 3.66 | 5.12 | 99.57 | 9.17 |
| Return On Assets (%) | 4.54 | -1.58 | -8.71 | 21.01 | -6.08 |
| Long Term Debt / Equity (X) | 0.17 | 0.61 | 1.38 | 4.63 | -5.84 |
| Total Debt / Equity (X) | 0.35 | 0.81 | 1.55 | 9.66 | -6.24 |
| Asset Turnover Ratio (%) | 0.83 | 0.72 | 0.55 | 0.82 | 0.30 |
| Current Ratio (X) | 1.45 | 1.35 | 1.36 | 0.52 | 0.59 |
| Quick Ratio (X) | 1.18 | 1.09 | 1.14 | 0.44 | 0.50 |
| Inventory Turnover Ratio (X) | 12.12 | 12.72 | 3.05 | 4.31 | 2.23 |
| Interest Coverage Ratio (X) | 8.87 | 3.51 | 1.71 | 5.13 | 0.81 |
| Interest Coverage Ratio (Post Tax) (X) | 4.49 | 0.54 | 0.51 | 3.23 | 0.65 |
| Enterprise Value (Cr.) | 396.90 | 401.32 | 381.55 | 501.74 | 229.87 |
| EV / Net Operating Revenue (X) | 2.87 | 3.61 | 4.10 | 2.59 | 2.67 |
| EV / EBITDA (X) | 19.68 | 23.37 | 18.85 | 4.86 | 10.82 |
| MarketCap / Net Operating Revenue (X) | 2.60 | 3.15 | 3.45 | 2.00 | 0.86 |
| Price / BV (X) | 3.48 | 5.14 | 7.07 | 29.17 | -2.89 |
| Price / Net Operating Revenue (X) | 2.60 | 3.15 | 3.45 | 2.00 | 0.86 |
| EarningsYield | 0.02 | -0.01 | -0.04 | 0.10 | -0.15 |
After reviewing the key financial ratios for Lyka Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.22. This value is below the healthy minimum of 5. It has increased from -0.79 (Mar 24) to 2.22, marking an increase of 3.01.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.22. This value is below the healthy minimum of 5. It has increased from -0.79 (Mar 24) to 2.22, marking an increase of 3.01.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.12. This value is within the healthy range. It has increased from 3.08 (Mar 24) to 4.12, marking an increase of 1.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 29.01. It has increased from 20.60 (Mar 24) to 29.01, marking an increase of 8.41.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 29.01. It has increased from 20.60 (Mar 24) to 29.01, marking an increase of 8.41.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 38.81. It has increased from 33.60 (Mar 24) to 38.81, marking an increase of 5.21.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 5.65. This value is within the healthy range. It has increased from 5.19 (Mar 24) to 5.65, marking an increase of 0.46.
- For PBIT / Share (Rs.), as of Mar 25, the value is 3.75. This value is within the healthy range. It has increased from 1.32 (Mar 24) to 3.75, marking an increase of 2.43.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.12. This value is within the healthy range. It has increased from -0.28 (Mar 24) to 3.12, marking an increase of 3.40.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.22. This value is within the healthy range. It has increased from -0.79 (Mar 24) to 2.22, marking an increase of 3.01.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 2.24. This value is within the healthy range. It has increased from -0.75 (Mar 24) to 2.24, marking an increase of 2.99.
- For PBDIT Margin (%), as of Mar 25, the value is 14.56. This value is within the healthy range. It has decreased from 15.44 (Mar 24) to 14.56, marking a decrease of 0.88.
- For PBIT Margin (%), as of Mar 25, the value is 9.67. This value is below the healthy minimum of 10. It has increased from 3.92 (Mar 24) to 9.67, marking an increase of 5.75.
- For PBT Margin (%), as of Mar 25, the value is 8.03. This value is below the healthy minimum of 10. It has increased from -0.83 (Mar 24) to 8.03, marking an increase of 8.86.
- For Net Profit Margin (%), as of Mar 25, the value is 5.72. This value is within the healthy range. It has increased from -2.35 (Mar 24) to 5.72, marking an increase of 8.07.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 5.78. This value is below the healthy minimum of 8. It has increased from -2.23 (Mar 24) to 5.78, marking an increase of 8.01.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.73. This value is below the healthy minimum of 15. It has increased from -3.65 (Mar 24) to 7.73, marking an increase of 11.38.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.33. This value is within the healthy range. It has increased from 3.66 (Mar 24) to 10.33, marking an increase of 6.67.
- For Return On Assets (%), as of Mar 25, the value is 4.54. This value is below the healthy minimum of 5. It has increased from -1.58 (Mar 24) to 4.54, marking an increase of 6.12.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.17. This value is below the healthy minimum of 0.2. It has decreased from 0.61 (Mar 24) to 0.17, marking a decrease of 0.44.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.35. This value is within the healthy range. It has decreased from 0.81 (Mar 24) to 0.35, marking a decrease of 0.46.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.83. It has increased from 0.72 (Mar 24) to 0.83, marking an increase of 0.11.
- For Current Ratio (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 1.5. It has increased from 1.35 (Mar 24) to 1.45, marking an increase of 0.10.
- For Quick Ratio (X), as of Mar 25, the value is 1.18. This value is within the healthy range. It has increased from 1.09 (Mar 24) to 1.18, marking an increase of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 12.12. This value exceeds the healthy maximum of 8. It has decreased from 12.72 (Mar 24) to 12.12, marking a decrease of 0.60.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.87. This value is within the healthy range. It has increased from 3.51 (Mar 24) to 8.87, marking an increase of 5.36.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.49. This value is within the healthy range. It has increased from 0.54 (Mar 24) to 4.49, marking an increase of 3.95.
- For Enterprise Value (Cr.), as of Mar 25, the value is 396.90. It has decreased from 401.32 (Mar 24) to 396.90, marking a decrease of 4.42.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.87. This value is within the healthy range. It has decreased from 3.61 (Mar 24) to 2.87, marking a decrease of 0.74.
- For EV / EBITDA (X), as of Mar 25, the value is 19.68. This value exceeds the healthy maximum of 15. It has decreased from 23.37 (Mar 24) to 19.68, marking a decrease of 3.69.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.60. This value is within the healthy range. It has decreased from 3.15 (Mar 24) to 2.60, marking a decrease of 0.55.
- For Price / BV (X), as of Mar 25, the value is 3.48. This value exceeds the healthy maximum of 3. It has decreased from 5.14 (Mar 24) to 3.48, marking a decrease of 1.66.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.60. This value is within the healthy range. It has decreased from 3.15 (Mar 24) to 2.60, marking a decrease of 0.55.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.01 (Mar 24) to 0.02, marking an increase of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lyka Labs Ltd:
- Net Profit Margin: 5.72%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.33% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.73% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.49
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.18
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 44.8 (Industry average Stock P/E: 55.81)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.35
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.72%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 4801/B & 4802/A, Ankleshwar Gujarat 393002 | companysecretary@lykalabs.com. http://www.lykalabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Babulal Jain | Chairman |
| Mr. Kunal Gandhi | Managing Director & CEO |
| Mr. Yogesh B Shah | WholeTime Director & CFO |
| Mr. Shashil Mendosa | Non Executive Director |
| Mr. Prashant Godha | Non Executive Director |
| Mrs. Dhara Shah | Independent Director |
| Mr. Neeraj Golas | Independent Director |
| Ms. Archana S Yadav | Independent Director |
FAQ
What is the intrinsic value of Lyka Labs Ltd?
Lyka Labs Ltd's intrinsic value (as of 09 November 2025) is 98.70 which is 4.89% higher the current market price of 94.10, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 336 Cr. market cap, FY2025-2026 high/low of 177/90.2, reserves of ₹68 Cr, and liabilities of 176 Cr.
What is the Market Cap of Lyka Labs Ltd?
The Market Cap of Lyka Labs Ltd is 336 Cr..
What is the current Stock Price of Lyka Labs Ltd as on 09 November 2025?
The current stock price of Lyka Labs Ltd as on 09 November 2025 is 94.1.
What is the High / Low of Lyka Labs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lyka Labs Ltd stocks is 177/90.2.
What is the Stock P/E of Lyka Labs Ltd?
The Stock P/E of Lyka Labs Ltd is 44.8.
What is the Book Value of Lyka Labs Ltd?
The Book Value of Lyka Labs Ltd is 29.0.
What is the Dividend Yield of Lyka Labs Ltd?
The Dividend Yield of Lyka Labs Ltd is 0.00 %.
What is the ROCE of Lyka Labs Ltd?
The ROCE of Lyka Labs Ltd is 9.91 %.
What is the ROE of Lyka Labs Ltd?
The ROE of Lyka Labs Ltd is 9.31 %.
What is the Face Value of Lyka Labs Ltd?
The Face Value of Lyka Labs Ltd is 10.0.